Cargando…

NEIM-02 DEVELOPMENT OF A DEEP LEARNING MODEL FOR DISCRIMINATING TRUE PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS

INTRODUCTION: Glioblastomas (GBMs) are highly aggressive tumors. Despite multimodal treatment, its median overall survival ranges between 16 and 20 months. The standard treatment regimen consists of surgical resection followed by concurrent chemoradiotherapy and adjuvant temozolomide. Despite temozo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moassefi, Mana, Faghani, Shahriar, Conte, Gian Marco, Rouzrokh, Pouria, Kowalchuk, Roman O, Trifiletti, Daniel, Erickson, BradleyJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354212/ http://dx.doi.org/10.1093/noajnl/vdac078.069

Ejemplares similares

Machine Learning and Deep Learning in Cardiothoracic Imaging: A Scoping Review
por: Khosravi, Bardia, et al.
Publicado: (2022)

Machine Learning in Cardiovascular Imaging: A Scoping Review of Published Literature
por: Rouzrokh, Pouria, et al.
Publicado: (2022)

NEIM-01 INCIDENCE AND DIAGNOSTIC TECHNIQUES FOR LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASIS
por: Henry, Katie, et al.
Publicado: (2022)

Glioblastoma pseudoprogression and true progression reveal spatially variable transcriptional differences
por: Wang, Wesley, et al.
Publicado: (2023)

NEIM-08 A PHASE II STUDY OF MULTIPARAMETRIC MR-GUIDED HIGH DOSE ADAPTIVE RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
por: Kim, Michelle, et al.
Publicado: (2022)

NEIM-04 LEVERAGING NOVEL NEUROIMAGING TECHNIQUES TO LINK BRAIN METASTASES AND LOCAL GENE EXPRESSION
por: Germann, Jurgen, et al.
Publicado: (2022)

BIMG-12. [18F]FLUCICLOVINE PET TO DISTINGUISH PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN POST-TREATMENT GLIOBLASTOMA
por: Nabavizadeh, Ali, et al.
Publicado: (2021)

Discriminators of pseudoprogression and true progression in high-grade gliomas: A systematic review and meta-analysis
por: Taylor, Chris, et al.
Publicado: (2022)

Validation of myasthenia gravis activity of daily living questionnaire: Persian version
por: Faghani, Shahriar, et al.
Publicado: (2022)

Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study
por: Brahm, Cyrillo G., et al.
Publicado: (2018)

Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation
por: Qian, Xiaohua, et al.
Publicado: (2016)

Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma
por: Verma, Gaurav, et al.
Publicado: (2018)

Pseudoprogression as an adverse event of glioblastoma therapy
por: Balaña, Carmen, et al.
Publicado: (2017)

FSMP-02. CHANGES IN GLUTAMINE METABOLISM INDUCED BY OXALOACETATE IN GLIOBLASTOMA
por: Ijare, Omkar, et al.
Publicado: (2021)

Discriminating pseudoprogression and true progression in diffuse infiltrating glioma using multi-parametric MRI data through deep learning
por: Lee, Joonsang, et al.
Publicado: (2020)

NEIM-03 A MULTICENTER PHASE 3 TRIAL IN PROGRESS: DIAGNOSTIC PERFORMANCE OF(18)F-FLUCICLOVINE PET FOR THE DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY (REVELATE)
por: Chao, Samuel, et al.
Publicado: (2022)

NEIM-07 DIFFERENTIAL DIAGNOSIS OF TUMOR RECURRENCE AND RADIATION NECROSIS AFTER STEREOTACTIC RADIOTHERAPY FOR BRAIN METASTASES WITH 320-ROW ADCT PERFUSION IMAGE AND T1/T2 MATCH: RADIOLOGICAL AND PATHOLOGICAL ANALYSIS
por: Mitsuya, Koichi, et al.
Publicado: (2022)

Restriction Spectrum Imaging Differentiates True Tumor Progression From Immune-Mediated Pseudoprogression: Case Report of a Patient With Glioblastoma
por: Daghighi, Shadi, et al.
Publicado: (2020)

Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

ETMM-02. PRECLINICAL MODELS REVEAL BRAIN-MICROENVIRONMENT SPECIFIC METABOLIC DEPENDENCIES IN GLIOBLASTOMA
por: Minami, Jenna, et al.
Publicado: (2021)

A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression
por: Zhang, Peng, et al.
Publicado: (2015)

Glioblastoma with brainstem leptomeningeal pseudoprogression following radiation therapy
por: Kinger, Nikhar, et al.
Publicado: (2019)

Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features
por: Li, Mingxiao, et al.
Publicado: (2021)

NEIM-05 FEASIBILITY OF NAVIGATED TRANSCRANIAL MAGNETIC STIMULATION (NTMS) BASED DIFFUSION TENSOR IMAGING (DTI) TRACTOGRAPHY OF MOTOR PATHWAYS IN PATIENTS UNDERGOING STEREOTACTIC RADIOSURGERY: A CROSS-SECTIONAL DOSIMETRIC AND PATIENT OUTCOMES ANALYSIS
por: Bronk, Julianna, et al.
Publicado: (2022)

Abstract screening using the automated tool Rayyan: results of effectiveness in three diagnostic test accuracy systematic reviews
por: Valizadeh, Amir, et al.
Publicado: (2022)

ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application
por: Funakoshi, Yusuke, et al.
Publicado: (2020)

True Progression versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis
por: Song, Yong Sub, et al.
Publicado: (2013)

SOUP-GAN: Super-Resolution MRI Using Generative Adversarial Networks
por: Zhang, Kuan, et al.
Publicado: (2022)

High levels of cellular proliferation predict pseudoprogression in glioblastoma patients
por: POULEAU, HENRI-BENJAMIN, et al.
Publicado: (2011)

Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review
por: Sidibe, Ingrid, et al.
Publicado: (2022)

Radiomic Analysis to Predict Histopathologically Confirmed Pseudoprogression in Glioblastoma Patients
por: McKenney, Anna Sophia, et al.
Publicado: (2022)

NEIM-14 PET/MRI DETECTS A RAPID DECREASE IN CEREBRAL BLOOD FLOW IN GLIOBLASTOMA FOLLOWING BEVACIZUMAB INFUSION
por: Thaw-Poon, Serena, et al.
Publicado: (2023)

Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation
por: Linhares, Paulo, et al.
Publicado: (2013)

Prediction of Pseudoprogression versus Progression using Machine Learning Algorithm in Glioblastoma
por: Jang, Bum-Sup, et al.
Publicado: (2018)

Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report
por: Zhao, Mingming, et al.
Publicado: (2022)

Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas
por: de Godoy, Laiz Laura, et al.
Publicado: (2023)

CLRM-02 SINGLE CENTER EXPERIENCE OF DOPAMINE ANTAGONIST ONC-201 FOR RECURRENT H3K27M-MUTANT GLIOBLASTOMA IN ADULTS
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma
por: Leone, Riccardo, et al.
Publicado: (2023)

Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps
por: Reimer, Caroline, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5qt0s08bi5h0sgj81gg4oes85d